Page 145 - CW E-Magazine (5-8-2025)

Pharmaceuticals Fertilisers

OVERSEAS PRESENCE UREA PRODUCTION

Natco Pharma to acquire 35.75% stake in South OIL forms new Joint Venture to set up Namrup IV

Africa’s Adcock Ingram fertiliser plant in Assam

Hyderabad-based Natco Pharma action will provide Natco Pharma with a Oil India Ltd. (OIL) has announced The JV aligns with the
said it has made an offer to acquire a well-established entry into the Southern the formation of a joint venture Government of India’s vision
35.75 percent stake in Adcock Ingram African market. It will also allow Natco company, Assam Valley Fertilizer and of achieving self-suffi ciency in
Holdings Ltd. (AIHL), South Africa, in Pharma to tap into new revenue streams Chemical Company Ltd. (AVFCCL), urea production and is backed
a Rs. 1,970-crore cash deal. and expand our footprint in one of the incorporated jointly with the Govern- by the Department of Fertilisers
largest and growing emerging markets, ment of Assam, National Fertilizers under the Ministry of Chemicals
The acquisition amounts to while providing a gateway to the African Ltd. (NFL), Hindustan Urvarak & and Fertilisers. The new Namrup
51,643,319 equity shares, resulting in continent.” Rasayan Ltd. (HURL), and Brahma- IV plant is expected to not
Natco’s shareholding reaching 35.75 35.75%, including a prior held stake,” putra Valley Fertilizer Corporation Ltd. only enhance domestic ferti-
percent of the paid-up equity share capi- it added. The transaction will be com- Founded in 1890 in South Africa, (BVFCL). liser availability but also catalyse
tal of AIHL in aggregate, the company pleted on or before December 31, 2025. AIHL is a pharmaceutical company opera- economic development and
informed in a press note. “It is envi- ting across four segments: prescription, The new company, incorporated on OIL has acquired an 18% equity employment in Assam.
saged that post-acquisition, Adcock Rajeev Nannapaneni, CEO & consumer, OTC, and hospitals. It has July 25, will spearhead the establish- stake in AVFCCL by subscribing to
Ingram will continue to operate as a Vice Chairman of Natco Pharma, said, a diverse portfolio of products ranging ment of the Namrup IV Ammonia-Urea 18,000 equity shares at Rs. 10 each, The new brownfi eld complex
private South African business, supported “Adcock Ingram maintains a leading from generic and branded formulations Complex in Namrup, Assam. This pro- contributing Rs. 1.8-lakh as initial within the existing premises of BVFCL,
by two substantial strategic sharehol- position in the South African pharma- to critical-care hospital products, as well ject aims to revitalise and modernise investment. The total subscribed capital Namrup, was approved by the Union
ders, Bidvest at 64.25% and Natco at ceutical market. The proposed trans- as consumer & home-care products. the region’s fertiliser infrastructure to of the company currently stands at Cabinet in March this year. Work on
meet the growing demand for urea in Rs. 10-lakh, consisting of 1,00,000 the project is expected to commence
QUALITY CONCERNS the Northeast and beyond. equity shares. by December.
Sun Pharma, Lupin, Dr. Reddy’s recall products FINANCIAL PERFORMANCE

in US market Coromandel International reports strong Q1 net profi t

Sun Pharma, Lupin and Dr. Reddy’s Mumbai-based Lupin is recalling prazole Delayed-release capsules. The and revenues
Laboratories are recalling drugs in the 58,968 bottles of a generic combina- medication is used to treat certain stom-
US market due to manufacturing issues tion medication used to treat high blood ach and oesophagus problems. Prince- Coromandel International Ltd. pro- ing and new markets. “The rock phos- overall shareholding in BMCC to 71.51
and product mix up, according to the pressure. Its Naples-based arm, Lupin ton-based Dr. Reddy’s Laboratories Inc. vides agri solutions, said an early mon- phate project at Senegal has stabilised percent.
US health regulator. Pharmaceuticals Inc., is recalling Lisin- initiated the Class II recall on June 30, soon helped it put up a good performance and is delivering consistent rock sup-
opril and Hydrochlorothiazide tablets 2025, USFDA stated. The affected lot in the fi rst quarter ended June 30, 2025. plies to phosphoric acid plants in India,” “The acquisition of additional stake
As per the latest Enforcement (USP 20mg/12.5mg). The affected lot was produced at the company’s Bachu- The Murugappa group company sells the company said in a statement. in BMCC is a strategic move to further
Report of US Food and Drug Administra- was manufactured at the company’s pally (Telangana)-based manufactur- fertilisers, crop protection chemicals, strengthen our backward integration in
tion (USFDA), the Mumbai-headquar- Nagpur-based manufacturing facility. ing facility. The recall is due to the bio-products, and speciality nutrients. The crop protection segment sales the phosphates value chain. With this,
tered Sun Pharmaceutical Industries As per the USFDA, the company initia- presence of foreign tablets/capsules, and margins grew by 31 percent and 75 Coromandel is reinforcing its com-
is recalling 5,448 bottles of a generic ted the Class II recall on June 20 due to USFDA said. It is due to the presence “An early monsoon resulted in percent, respectively, during the quarter, mitment to securing vital raw material
medication in the US. Princeton-based “product mix up”. This product is being of foreign Divalproex Sodium exten- higher crop sowings and improved agri led by a strong performance in the sources and ensuring long-term supply
Sun Pharmaceutical Industries Inc. is recalled because of a complaint received ded-release 250mg tablets in a bottle inputs consumption. The growth is also domestic and international markets. chain resilience,” he said.
recalling the affected lot of Lisdexam- that a sealed bottle of lisinopril and hydro- of omeprazole capsules, it added. driven by procurement effi ciencies,
fetamine Dimesylate capsules (60-mg) chlorothiazide tablets 20mg/12.5 mg operational excellence and effective The board of directors has approved “Our backward integration pro-
due to “Failed Dissolution Specifi ca- had a foreign tablet identifi ed as ataza- As per the USFDA, a Class-II recall marketing initiatives,” said Mr. S. Sankara- the acquisition of an additional 17.69 jects for phosphoric and sulphuric acid
tions”, the US health regulator stated. navir and ritonavir tablet 300mg/100mg, is initiated when the use of, or exposure subramanian, Managing Director and percent issued share capital of Bao- plants at Kakinada are progressing well
The medication is used to treat attention the US health regulator stated. to, a violative product may lead to tem- CEO, Coromandel International. bab Mining and Chemicals Corpora- and are likel0y to be commissioned
defi cit hyperactivity disorder (ADHD). porary or medically reversible health tion SA, Senegal (BMCC), through its by the end of the fourth quarter. We
The drug fi rm initiated the Class II In another fi ling, the US health reg- consequences, or when the likelihood The company’s phosphatic fertiliser wholly-owned subsidiary, Coromandel have also initiated the groundwork for
recall in the US on June 16 this year, ulator said that Dr. Reddy’s Laborato- of serious adverse health outcomes is business recorded 31 percent volume Chemicals Ltd. (CCL), for a conside- setting up a 7.5-lakh-tonne fertiliser
it added. ries is recalling 1,476 bottles of Ome- minimal. growth, improving its presence in exist- ration of $7.70-mn. This will take the granulation facility at Kakinada,” he said.

144 Chemical Weekly August 5, 2025 Chemical Weekly August 5, 2025 145

Contents Index to Advertisers Index to Products Advertised